#2249
Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma
Introduction:
The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Davi' M
Authors:
Zambon G,
Cosaro E,
Cingarlini S,
Trombetta M,
Landoni L,
Keywords:
pasireotide,
malignant insulinoma,
hypoglycemia,
#1226
Follow Up of ≤ 2 cm Non Functioning Pancreatic NETs in Patients with MEN1 Treated with Conservative Approach
Introduction:
There is a current trend for conservative treatment of non functioning pancreatic NET (NF-PNETs), ≤ 2 cm, in patients with MEN1, which are reported to be associated with low risk of metastasis and death.
Conference:
12th Annual ENETSConcerence (2015)
Presenting Author:
Davi' M
Authors:
Davì M,
Cosaro E,
Malpaga A,
Butturini G,
Ortolani S,
Keywords:
Pancreatic neuroendocrine tumor,
MEN1,
#858
Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?
Introduction:
Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
davi' m
Authors:
Davì M,
Cingarlini S,
Butturini G,
Capelli P,
Scarpa A,
Keywords:
Everolimus,
pancreatic NET,
ectopic Cushing syndrome,
#102
Presentation and outcome of pancreaticoduodenal tumors in Multiple Endocrine Neoplasia type 1 (MEN 1) syndrome
Introduction:
Multiple endocrine neoplasia type 1 (MEN 1) is a rare autosomal dominant condition characterized by the development of parathyroid, pancreaticoduodenal endocrine and pituitaty tumors. Pancreaticduodenal endocrine tumors (PDETs) are a frequent manifestation of MEN 1, with a prevalence ranging from 30 to 75%, and represent a major cause of death in one-third of patients. There is continuing debate on their management, mainly on the optimal surgical strategy, due to their multicentricity and high recurrence rate.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Authors:
Davi' M,
Boninsegna L,
Toaiari M,
Scarpa A,
Francia G,
Keywords:
pancreaticoduodenal endocrine tumors,
MEN 1,
